180079-94-1

Basic information

• Product Name: [2-(3-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: tert-butyl 3-aMinophenethylcarbaMate;Carbamic acid, N-[2-(3-aminophenyl)ethyl]-, 1,1-dimethylethyl ester;3-[2-(Boc-amino)ethyl]aniline;[2-(3-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
• CAS NO: 180079-94-1
• Molecular Formula: C₁₃H₂₀N₂O₂
• Molecular Weight: 236.31
• Product Categories: pharmacetical
• Mol File: 180079-94-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 400.3±28.0 °C(Predicted)
• Appearance: /
• Density: 1.077±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.69±0.46(Predicted)
• CAS DataBase Reference: [2-(3-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: [2-(3-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(180079-94-1)
• EPA Substance Registry System: [2-(3-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(180079-94-1)

Safety Data

• Hazardous Substances Data: 180079-94-1(Hazardous Substances Data)

Usage

General Description

The chemical [2-(3-amino-phenyl)-ethyl]-carbamic acid tert-butyl ester, also known as Tert-butyl N-(3-aminophenethyl)carbamate, is an organic compound with the molecular formula C13H19N3O2. It is an amine derivative and ester of carbamic acid, and it is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound has potential applications in the fields of medicinal chemistry and biochemistry due to its pharmacological properties. It is important to handle this chemical with care and follow safety protocols when working with it in a laboratory setting.

Upstream product

• 619-23-8 3-Nitrobenzyl chloride 
• 83304-13-6 2-(3-nitrophenyl)ethylamine 
• 180079-93-0 N-(3-nitrophenylmethyl)methylcarbamic acid t-butyl ester 
• 4623-24-9 2-(3-aminophenyl)acetonitrile 
• 621-50-1 (3-nitrophenyl)acetonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 76935-75-6 2-(3-aminophenyl)ethylamine 

Downstream Products

• 1185465-54-6 tert-butyl [2-(3-{[(1-adamantylamino)carbonyl]amino}phenyl)-ethyl]carbamate 
• 1185465-25-1 tert-butyl [2-(3-isocyanatophenyl)ethyl]carbamate 
• 1185463-88-0 N-(2,6-dichlorobenzyl)-N'-[3-(2-{[(2R,S)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}ethyl)phenyl]urea 
• 1185463-82-4 N-(diphenylmethyl)-N'-[3-(2-{[(2R,S)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}ethyl)phenyl]urea 
• 1185463-90-4 N-biphenyl-2-yl-N'-[3-(2-{[(2RS)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}ethyl)phenyl]urea 
• 1185464-03-2 N-[3-(2-{[(2R,S)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]-amino}ethyl)phenyl]-N'-(3-phenoxyphenyl)urea 
• 1185464-34-9 N-(4-tert-butylbenzyl)-N'-[3-(2-{[(2R,S)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydro-quinolin-5-yl)ethyl]amino}ethyl)phenyl]urea 
• 1185463-83-5 N-[3-(2-{[(2R,S)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]-amino}ethyl)phenyl]-N'-phenylurea 
• 1185465-48-8 tert-butyl (2-{3-[(anilinocarbonyl)amino]phenyl}ethyl)carbamate 
• 1185465-18-2 tert-butyl [2-(3-{[(benzylamino)carbonyl]amino}phenyl)ethyl]-carbamate 
• 1185465-29-5 tert-butyl {2-[3-({[(2-phenylethyl)amino]carbonyl}amino)phenyl]-ethyl}carbamate 
• 1185465-33-1 tert-butyl {2-[3-({[(3-phenylpropyl)amino]carbonyl}amino)phenyl]-ethyl}carbamate 
• 1185465-22-8 tert-butyl {2-[3-({[(2-methoxybenzyl)amino]carbonyl}amino)phenyl]-ethyl}carbamate 
• 1185465-26-2 tert-butyl {2-[3-({[(4-fluorobenzyl)amino]carbonyl}amino)phenyl]-ethyl}carbamate 

Relevant articles and documents

Cannabinoid receptor light-operated ligand and preparation method and application thereof

The invention relates to the technical field of biology, in particular to a novel cannabinoid receptor light-operated ligand and a preparation method and application thereof. Disclosed is the cannabinoid receptor light-operated ligand or the isomer prodrug, the solvate and the pharmaceutically acceptable salt of the cannabinoid receptor light-operated ligand, wherein the structural formula of thecannabinoid receptor light-operated ligand is A-linker-B; A is a transmembrane domain ligand structure, and B is a light-operated element; Linker is a subunit which is linear and has no activity on acannabinoid receptor light-operated ligand. According to the invention, the cannabinoid receptor ligand is integrated with azobenzene through a proper connector, so that the ligand configuration is changed under an illumination condition, and the activation or inhibition state of the cannabinoid receptor is regulated and controlled.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

BICYCLOANILINE DERIVATIVE

The invention relates to a compound of a general formula (I): wherein A1 and A2 each mean a nitrogen atom or an optionally-substituted methine group; Ring B means a 5-membered to 7-membered aliphatic ring, or a spiro or bicyclo ring formed from the aliphatic ring and any other 3-membered to 7-membered aliphatic ring; R1 means a hydrogen atom, or an optionally-substituted C1-C6 alkyl group, or an optionally-substituted aryl, aralkyl or heteroaryl group; R2 means an optionally-substituted aryl, aralkyl or heteroaryl group; and X means a group of =NH or =O, etc. Based on its excellent Wee1 kinase-inhibitory effect, the compound of the invention has cell growth-inhibitory effect and has an additive/synergistic effect with any other anticancer agent, and is therefore useful in the field of medicine.